We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+3.94%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.45B
AUM Growth
+$719M
Cap. Flow
+$643M
Cap. Flow %
6.8%
Top 10 Hldgs %
29.09%
Holding
237
New
15
Increased
96
Reduced
78
Closed
21

Top Buys

Rank Stock Value
1
ACCD
Accolade Inc
ACCD
+$56.6M
2
RVMD icon
Revolution Medicines
RVMD
+$46M
3
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$43.7M
4
EPIX
ESSA Pharma
EPIX
+$42.4M
5
BDX icon
Becton Dickinson
BDX
+$33.4M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$86.9M
2
HALO icon
Halozyme
HALO
+$47.2M
3
GNMK
GenMark Diagnostics, Inc
GNMK
+$38.1M
4
ESPR
Esperion Therapeutics
ESPR
+$33.9M
5
CHNG
Change Healthcare Inc. Common Stock
CHNG
+$33.3M

Sector Composition

Rank Sector Weight
1 Healthcare 95.93%
2 Industrials 0.88%
3 Technology 0.47%
4 Consumer Discretionary 0.04%
5 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDX icon
26
Becton Dickinson
BDX
$42.9B
$112M 1.19%
472,489
+136,539
+41% +$33.4M
ESPR
27
DELISTED
Esperion Therapeutics
ESPR
$112M 1.18%
3,989,164
-1,149,287
-22% -$33.9M
CI icon
28
Cigna
CI
$75.1B
$108M 1.15%
448,162
+34,954
+8% +$7.79M
SRRK icon
29
Scholar Rock
SRRK
$6.28B
$108M 1.14%
2,131,125
-155,526
-7% -$8.6M
MYOV
30
DELISTED
Myovant Sciences Ltd.
MYOV
$107M 1.13%
5,194,039
+390,000
+8% +$8.88M
DHR icon
31
Danaher
DHR
$143B
$106M 1.13%
533,702
-68,418
-11% -$13.9M
MTEM
32
DELISTED
Molecular Templates, Inc.
MTEM
$103M 1.09%
543,207
+115,718
+27% +$20.3M
JAZZ icon
33
Jazz Pharmaceuticals
JAZZ
$15.4B
$90.5M 0.96%
550,650
+161,785
+42% +$26.6M
BSX icon
34
Boston Scientific
BSX
$65.7B
$89.9M 0.95%
2,326,787
+116,928
+5% +$4.43M
AXNX
35
DELISTED
Axonics, Inc. Common Stock
AXNX
$87.2M 0.92%
1,456,274
+287,296
+25% +$15.6M
INSM icon
36
Insmed
INSM
$23.6B
$84.4M 0.89%
2,477,166
+860,166
+53% +$32.9M
SYK icon
37
Stryker
SYK
$123B
$83.9M 0.89%
344,514
+6,499
+2% +$1.56M
CNC icon
38
Centene
CNC
$32.9B
$82.5M 0.87%
1,290,597
+105,550
+9% +$6.54M
NKTR icon
39
Nektar Therapeutics
NKTR
$2.22B
$79.1M 0.84%
263,640
+5,889
+2% +$1.83M
ALGN icon
40
Align Technology
ALGN
$12.5B
$78M 0.82%
143,960
+31,192
+28% +$17.2M
DXCM icon
41
DexCom
DXCM
$29.5B
$77.7M 0.82%
864,772
+11,544
+1% +$1.08M
EW icon
42
Edwards Lifesciences
EW
$49.2B
$74.5M 0.79%
890,256
+63,338
+8% +$5.35M
HRC
43
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$73M 0.77%
660,628
+8,103
+1% +$844K
EVH icon
44
Evolent Health
EVH
$660M
$71.3M 0.75%
3,528,547
+379,436
+12% +$7.22M
ACCD
45
DELISTED
Accolade Inc
ACCD
$70.8M 0.75%
1,561,121
+1,175,813
+305% +$56.6M
HCA icon
46
HCA Healthcare
HCA
$82.2B
$70.5M 0.75%
374,563
+7,519
+2% +$1.33M
GBIO
47
DELISTED
Generation Bio
GBIO
$68.1M 0.72%
239,318
+6,000
+3% +$1.92M
HOLX
48
DELISTED
Hologic
HOLX
$68M 0.72%
913,752
+5,164
+0.6% +$392K
RLAY icon
49
Relay Therapeutics
RLAY
$4.23B
$66.8M 0.71%
1,931,344
+521,987
+37% +$22.7M
EXEL icon
50
Exelixis
EXEL
$14.1B
$66.5M 0.7%
2,944,500
– –
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2021 Portfolio in Review

As of Q1 2021, Bellevue Group held 237 positions worth $9.45B, up 8.2% from $8.73B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Group deployed $643M of net new capital in Q1 2021, opening 15 new positions and adding to 96 existing holdings. Its largest new stake was ESSA Pharma: 1,825,814 shares worth $53M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was GW Pharmaceuticals Plc American Depositary Shares, an estimated $86.9M trimmed.

  • Bellevue Group's largest Q1 2021 buy was ESSA Pharma: 1,825,814 shares worth $53M.
  • Bellevue Group added most to Accolade Inc in Q1 2021, an estimated $56.6M increase.
  • Bellevue Group's biggest Q1 2021 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $86.9M.
  • Bellevue Group fully exited GenMark Diagnostics, Inc in Q1 2021, selling an estimated $38.1M.
  • Bellevue Group's ten largest holdings make up 29% of its $9.45B portfolio in Q1 2021.
  • Bellevue Group opened 15 new positions and closed 21 in Q1 2021.
  • Bellevue Group's portfolio value rose 8.2% quarter-over-quarter to $9.45B.

Based on Bellevue Group's 13F filing for Q1 2021, filed 12 May 2021.